Mechanism of treating hyperlipidemia with Ningzhi capsule based on network pharmacology and molecular docking technology

doi:10.16352/j.issn.1001-6325.2024.03.0346

Abstract

Abstract: Objective To screen the potential pharmacological targets of Ningzhi capsule, a lipid-lowering traditional Chinese medicine, and explore its mechanism of effect. Methods The components and predicted targets of Ningzhi capsule′s constituent drugs were obtained from BATMAN-TCM database. Hyperlipidemia-related targets were obtained from DisGeNET and GeneCards databases. The Venny2.1.0 tool was used to map drug targets and disease targets to obtain common targets as potential pharmacological targets. Protein-protein interaction analysis (STRING), gene ontology and pathway enrichment analysis (DAVID) were performed for the common targets. Finally, Swiss dock was used for molecular docking verification. Results A total of 1 432 predicted targets of Ningzhi capsule and 87 targets related to hyperlipidemia were found and 32 common targets were screened which covered 64 potential pharmacological ingredients of Ningzhi capsule. Potential pharmacological targets were most abundant for turmeric root-tuber, turmeric and cattail pollen, and potential pharmacological ingredients were most abundant for sickle senna seed, turmeric and turmeric root-tuber. Apolipoprotein E (APOE), nitric oxide synthase 3 (NOS3) and peroxisome proliferator activated receptor alpha (PPARA) had the highest hyperlipidemia correlation scores and more protein interactions, which were potential core targets. The biological processes related to DNA transcription were significantly enriched. Cholesterol metabolism, cGMP-PKG and PPAR signaling pathways were involved with APOE, NOS3 and PPARA, respectively. Molecular docking showed good binding activity. Conclusions There are many potential pharmacological ingredients of Ningzhi capsule and the key components for lowering lipids include turmeric root-tuber, turmeric, cattail pollen and sickle senna seed. APOE, NOS3 and PPARA are believed to be the key targets for lowering lipids with potential mechanism related to cholesterol metabolism, cGMP-PKG and PPAR signaling pathways.

Key words: Ningzhi capsule, hyperlipidemia, network pharmacology, target, pathway

CLC Number:

R285

XIE Hao, LI Yaoyang, ZHAO Bin, YANG Dan, WU Qunli. Mechanism of treating hyperlipidemia with Ningzhi capsule based on network pharmacology and molecular docking technology[J]. Basic & Clinical Medicine, 2024, 44(3): 346-351.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/10.16352/j.issn.1001-6325.2024.03.0346

http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/Y2024/V44/I3/346

References 11

[1]	国家卫生健康委员会疾病预防控制局. 中国居民营养与慢性病状况报告 2020[M]. 北京: 人民卫生出版社, 2020: 73-75.
[2]	马丽媛, 王增武, 樊静, 等. 《中国心血管健康与疾病报告2022》要点解读[J]. 中国全科医学, 2023, 26: 3975-3994.
[3]	中国血脂管理指南修订联合专家委员会. 中国血脂管理指南(2023年)[J]. 中国循环杂志, 2023, 38: 237-271.
[4]	吴群励, 杨丹. 梁晓春教授治疗血脂异常的经验[J]. 中国临床医生杂志, 2020, 48: 1506-1508.
[5]	梁晓春,郭赛珊,王香定, 等. 降脂中药片降脂及抗脂质过氧化损伤的临床研究及机制探讨[J]. 中国中西医结合杂志, 1994, 14: 139-141+131.
[6]	梁晓春, 郭赛珊, 田国庆, 等. 宁脂胶囊对Wistar大鼠脂代谢的影响[J]. 北京中医, 2006, 25: 752-753.
[7]	王靖臣. 基于液质联用技术的血浆中胆固醇酯及鞘脂的分析方法的建立及应用[D]. 武汉:华中科技大学, 2022: 37-47.
[8]	Yuan Y, Li S, Mai K, et al. The effect of dietary arachidonic acid (ARA) on growth performance, fatty acid composition and expression of ARA metabolism-related genes in larval half-smooth tongue sole (Cynoglossus semilaevis)[J]. Br J Nutr, 2015, 113: 1518-1530.
[9]	侯孟杰, 赵娜, 黄富强, 等. 载脂蛋白E通过降低高尔基体膜蛋白73表达抑制小鼠肝癌细胞系增殖[J]. 基础医学与临床, 2023, 43: 762-770.
[10]	Lan T, Li Q, Chang M, et al. Lei-gong-gen formula granule attenuates hyperlipidemia in rats via cGMP-PKG signaling pathway[J]. J Ethnopharmacol, 2020, 260: 112989. doi: 10.1016/j.jep.2020.112989.
[11]	Montaigne D, Butruille L, Staels B. PPAR control of metabolism and cardiovascular functions[J]. Nat Rev Cardiol, 2021, 18: 809-823.

[1]	XU Lu, ZHANG Dongyu, WANG Ruifeng. Therapeutic effect of pachymic acid on Helicobacter pylori-associated gastritis in rats by regulating the PI3K/AKT/NF-κB signaling pathway [J]. Basic & Clinical Medicine, 2024, 44(4): 489-495.
[2]	WANG Zihao, XIA Xiaochao, LI Shun. Research progress on the role of transmembrane proteins in malignant tumors [J]. Basic & Clinical Medicine, 2024, 44(3): 398-402.
[3]	HAN Huijing, WU Hong, GE Yin, QIAO Juan. Dexmedetomidine alleviates lung tissue injury of rat models with ventilator-associated lung injury [J]. Basic & Clinical Medicine, 2024, 44(3): 339-345.
[4]	CHEN Weiwei, LIAO Huang, SHI Zhenhong, LUO Ying. FHL2 regulates THP-1 macrophage foaming through NF-κB signaling pathway [J]. Basic & Clinical Medicine, 2024, 44(2): 204-209.
[5]	ZHANG Xiuli, HU Xiaogang, MO Jun, CHEN Ling. Guanxinning tablet alleviates carotid atherosclerotic plaque injury in rats [J]. Basic & Clinical Medicine, 2024, 44(2): 192-198.
[6]	DENG Juan, WANG Xiufang, SUN Ruiqing. Wogonin promotes Th17/Treg cell balance in rat models with autoimmune hepatitis [J]. Basic & Clinical Medicine, 2024, 44(1): 77-83.
[7]	PAN Shan, LIN Kengqiang, CHEN Shuxing. Pemetrexed inhibits the proliferation of lung adenocarcinoma cell line A549 [J]. Basic & Clinical Medicine, 2023, 43(9): 1359-1363.
[8]	WANG Qiong, DONG Qianlan, ZHU Yanting, JIN Gang, ZHANG Linping. Platycodon D attenuates renal ischemia-reperfusion injury in rats [J]. Basic & Clinical Medicine, 2023, 43(8): 1222-1228.
[9]	MIAO Miao, LIU Yan, ZHANG Huan, ZHAO Huichao, LI Zhuofan, ZHANG Haolan, YUAN Panpan. Expression of death receptor apoptosis pathway- correlated factors in pancreatic tissue of mouse diabetic model [J]. Basic & Clinical Medicine, 2023, 43(8): 1254-1258.
[10]	WANG Fan, DENG Yongzhi. Advances on the role and molecular mechanism of microRNAs in cardiac hypertrophy [J]. Basic & Clinical Medicine, 2023, 43(7): 1167-1170.
[11]	LI Zhuoting, SHANG Yingxu, WANG Haiyan, JIANG Qiao, DING Baoquan, LI Jing, ZHAO Chunhua. Mesenchymal stem cell-engineered DNA nanostructures and the application in targeted delivery to the lungs of mice [J]. Basic & Clinical Medicine, 2023, 43(7): 1110-1116.
[12]	QIN Yuchun, KUANG Xiangdong, CAI Linzai, XIE Jingchen, CHEN Shan. Dihydroartemisinin alleviates lung injury in rat models with chronic obstructive pulmonary disease(COPD) [J]. Basic & Clinical Medicine, 2023, 43(3): 427-432.
[13]	WANG Hui, SU Xian, ZHANG Yingying, CHU Zhanya, SUN Zhaohui, ZHANG Jinling, ZHANG Qianqian. Isoramin attenuates retinal cell apoptosis in diabetes retinopathy rats [J]. Basic & Clinical Medicine, 2023, 43(2): 265-270.
[14]	LIU Tingting, HAN Chao, ZHAO Xiaoling, KONG Weimin. Metformin inhibits proliferation and promotes apoptosis of human cervical squamous cell carcinoma cell lines SiHa and CaSki [J]. Basic & Clinical Medicine, 2023, 43(2): 283-288.
[15]	YANG Mengdi, DING Yulu, WANG Yujie, HE Fengying, SUN Linnan, ZHEN Donghu. Research progress on the role of microRNA in diabetic osteoporosis [J]. Basic & Clinical Medicine, 2023, 43(2): 311-316.